Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Angiodynamics Inc receives FDA clearance for DuraMax Dialysis Catheter with BioFlo Technology to reduce Catheter-Related Thrombus


Friday, 7 Mar 2014 06:30am EST 

Angiodynamics Inc:U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.This marks third U.S. clearance of BioFlo product line in company's Vascular Access business.Indicated for use in attaining long-term vascular access for hemodialysis and apheresis, AngioDynamics expects a commercial launch in fourth quarter of fiscal year 2014. 

Company Quote

14.6
-0.09 -0.61%
31 Jul 2014